Regulation of SOCS3-STAT3 in urate-induced cytokine production in human myeloid cells

• Published in: Joint, bone, spine : revue du rhumatisme bone, spine : revue du rhumatisme, 2024-05, Vol.91 (3), p.105698-105698, Article 105698
• Main Authors: Badii, Medeea, Klück, Viola, Gaal, Orsolya, Cabău, Georgiana, Hotea, Ioana, Nica, Valentin, Mirea, Andreea M., Bojan, Anca, Zdrenghea, Mihnea, Novakovic, Boris, Merriman, Tony R., Liu, Zhaoli, Li, Yang, Xu, Cheng-Jian, Pamfil, Cristina, Rednic, Simona, Popp, Radu A., Crişan, Tania O., Joosten, Leo A.B.
• Format: Article
• Language: English
• Subjects: Cells, Cultured; Cytokines - metabolism; DNA Methylation; Female; Gout; Gout - genetics; Gout - metabolism; Humans; Hyperuricemia; Hyperuricemia - metabolism; Inflammation; Janus Kinase 2 - metabolism; Leukocytes, Mononuclear - drug effects; Leukocytes, Mononuclear - metabolism; Male; Middle Aged; Myeloid Cells - drug effects; Myeloid Cells - metabolism; SOCS3; STAT3; STAT3 Transcription Factor - metabolism; Suppressor of Cytokine Signaling 3 Protein - genetics; Suppressor of Cytokine Signaling 3 Protein - metabolism; Uric Acid - pharmacology
• ISSN: 1297-319X; 1778-7254
• DOI: 10.1016/j.jbspin.2024.105698

•Urate-primed PBMCs of hyperuricemic and gout patients show dysregulated cytokine production.•SOCS3 is enhanced in urate-primed myeloid cells, and this is conserved after a second stimulation with LPS.•pSTAT3 is downregulated by urate treatment in vitro, concomitant with reduction of IL-1Ra.•Urate-priming effect is not observed in patients with constitutively activated STAT3. Hyperuricaemia is necessary for gout. High urate concentrations have been linked to inflammation in mononuclear cells. Here, we explore the role of the suppressor of cytokine signaling 3 (SOCS3) in urate-induced inflammation. Peripheral blood mononuclear cells (PBMCs) from gout patients, hyperuricemic and normouricemic individuals were cultured for 24h with varying concentrations of soluble urate, followed by 24h restimulation with lipopolysaccharides (LPS)±monosodium urate (MSU) crystals. Transcriptomic profiling was performed using RNA-Sequencing. DNA methylation was assessed using Illumina Infinium® MethylationEPIC BeadChip system (EPIC array). Phosphorylation of signal transducer and activator of transcription 3 (STAT3) was determined by flow cytometry. Cytokine responses were also assessed in PBMCs from patients with JAK2 V617F tyrosine kinase mutation. PBMCs pre-treated with urate produced more interleukin-1beta (IL-1β) and interleukin-6 (IL-6) and less interleukin-1 receptor anatagonist (IL-1Ra) after LPS simulation. In vitro, urate treatment enhanced SOCS3 expression in control monocytes but no DNA methylation changes were observed at the SOCS3 gene. A dose-dependent reduction in phosphorylated STAT3 concomitant with a decrease in IL-1Ra was observed with increasing concentrations of urate. PBMCs with constitutively activated STAT3 (JAK2 V617F mutation) could not be primed by urate. In vitro, urate exposure increased SOCS3 expression, while urate priming, and subsequent stimulation resulted in decreased STAT3 phosphorylation and IL-1Ra production. There was no evidence that DNA methylation constitutes a regulatory mechanism of SOCS3. Elevated SOCS3 and reduced pSTAT3 could play a role in urate-induced hyperinflammation since urate priming had no effect in PBMCs from patients with constitutively activated STAT3.